Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CPT1C promotes human mesenchymal stem cells survival under glucose deprivation through the modulation of autophagy

  • Roa Mansergas, Xavier
  • Fadó Andrés, Rut
  • Atari Abouassi, Maher
  • Mir, Joan Francesc
  • Muley Vilamú, Helena
  • Serra, Dolors
  • Casals i Farré, Núria
Tis work was supported by the Ministry of Spain (SAF2014-52223-C2-1-R and SAF2017-82813-C3-3R and granted to DS, and SAF2014-52223-C2-2-R and SAF2017-82813-C3-3R granted to NC), all grants co-funded by Fondos Europeos de Desarrollo Regional de la Unión Europea –FEDER-), the Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (Grant CB06/03/0001 granted to DS), the Generalitat de Catalunya (2014SGR465 granted to DS and NC), Fundació La Marató de TV3 (201627.30.31 granted to DS and NC), CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII. Te funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Dr. Antonio Zorzano and Dr. David Sebastian for assistance with the extracellular fux analysis., Human mesenchymal stem cells (hMSCs) are widely used in regenerative medicine. In some applications, they must survive under low nutrient conditions engendered by avascularity. Strategies to improve hMSCs survival may be of high relevance in tissue engineering. Carnitine palmitoyltransferase 1 C (CPT1C) is a pseudoenzyme exclusively expressed in neurons and cancer cells. In the present study, we show that CPT1C is also expressed in hMSCs and protects them against glucose starvation, glycolysis inhibition, and oxygen/glucose deprivation. CPT1C overexpression in hMSCs did not increase fatty acid oxidation capacity, indicating that the role of CPT1C in these cells is different from that described in tumor cells. The increased survival of CPT1C-overexpressing hMSCs observed during glucose deficiency was found to be the result of autophagy enhancement, leading to a greater number of lipid droplets and increased intracellular ATP levels. In fact, inhibition of autophagy or lipolysis was observed to completely block the protective effects of CPT1C. Our results indicate that CPT1C-mediated autophagy enhancement in glucose deprivation conditions allows a greater availability of lipids to be used as fuel substrate for ATP generation, revealing a new role of CPT1C in stem cell adaptation to low nutrient environments., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hypothalamic endocannabinoids in obesity: an old story with new challenges

  • Miralpeix , Cristina
  • Reguera, Ana Cristina
  • Fosch, Anna
  • Zagmutt, Sebastián
  • Casals i Farré, Núria
  • Cota, Daniela
  • Rodríguez-Rodríguez, Rosalía
The author’s work is supported by the Spanish MINECO (Ministerio de Economía, Industria y Competitividad), AEI (Agencia Estatal de Investigación), FEDER (Fondo Europeo de Desarrollo Regional) (Grants SAF2017-82813-C3-3-R to N.C. and R.R-R, PID2020-114953RB-C22 to N.C. and R.R-R, by MCIN/AEI /10.13039/501100011033, and PCI2018-092997/AEI to R.R.-R), INSERM (Institut National de la Santé et de la Recherche Médicale), Nouvelle Aquitaine Region and ANR (ANR-18-CE14-0029 MitObesity, Labex BRAIN ANR-10-LABX-43, ANR-10-EQX-008–1 OPTOPATH, ANR-17-CE14-0007 BABrain to D.C.). C.M. was granted with a Fondation pour la Recherche Médicale (FRM) fellowship (SPF 202004011774) and A.C.R. with a fellowship from the Catalan Agència de Gestió d’Ajuts Universitaris i de la Recerca (AGAUR)., The crucial role of the hypothalamus in the pathogenesis of obesity is widely recognized, while the precise molecular and cellular mechanisms involved are the focus of intense research. A disrupted endocannabinoid system, which critically modulates feeding and metabolic functions, through central and peripheral mechanisms, is a landmark indicator of obesity, as corroborated by investigations centered on the cannabinoid receptor CB1, considered to offer promise in terms of pharmacologically targeted treatment for obesity. In recent years, novel insights have been obtained, not only into relation to the mode of action of CB receptors, but also CB ligands, non-CB receptors, and metabolizing enzymes considered to be part of the endocannabinoid system (particularly the hypothalamus). The outcome has been a substantial expansion in knowledge of this complex signaling system and in drug development. Here we review recent literature, providing further evidence on the role of hypothalamic endocannabinoids in regulating energy balance and the implication for the pathophysiology of obesity. We discuss how these lipids are dynamically regulated in obesity onset, by diet and metabolic hormones in specific hypothalamic neurons, the impact of gender, and the role of endocannabinoid metabolizing enzymes as promising targets for tackling obesity and related diseases., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Liver CPT1A gene therapy reduces diet‐induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

  • Weber, Minéia
  • Mera, Paula
  • Casas, Josefina
  • Salvador, Javier
  • Rodríguez, Amaia
  • Alonso, Sergio
  • Sebastián, David
  • Soler-Vázquez, M. Carmen
  • Montironi, Carla
  • Recalde, Sandra
  • Fucho, Raquel
  • Calderón-Domínguez, María
  • Mir, Joan Francesc
  • Bartrons, Ramon
  • Escola-Gil, Joan Carles
  • Sánchez-Infantes, David
  • Zorzano, Antonio
  • Llorente-Cortes, Vicenta
  • Casals i Farré, Núria
  • Valentí, Víctor
  • Frühbeck, Gema
  • Herrero Rodríguez, Laura
  • Serra, Dolors
We thank Gloria González-Aseguinolaza for kindly supplying the EalbAATp promoter. Financial support statement: This study was supported by the Ministry of Spain (MINECO) (SAF2014-52223-C2-1-R to DS, SAF2017-83813-C3-1-R to DS and LH, SAF2017-82813-C3-3R to NC co-financed by the European Regional Development Fund [ERDF], a doctoral fellowship to JFM, and a Juan de la Cierva—Incorporación research fellowship [IJCI-2016-28313] to PM and DS), the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (CB06/03/0001 to DS), the Government of Catalonia (2014SGR465 to DS), Instituto de Salud Carlos III (FISPI18/01584 to VL-C, FIS-PI17/00412 to RB, FIS PI18/01484 to SA and FIS17/01455 to DS-I, Miguel Servet Fund CP15/00106 to DS-I and Rio Hortega grant (CM19/00039) to CM) and co-financed by the European Regional Development Fund (ERDF), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) to JC-EG, the Fundació La Marató de TV3 (201627-30 to DS and 201627-31 to NC), the European Foundation for the Study of Diabetes (EFSD)/Lilly and EFSD/Janssen-Rising Star and L'Oréal-UNESCO “For Women in Science” research fellowships to LH, a doctoral fellowship from the Ciência sem Fronteiras-CNPq (237976/2012-9) to MW. Figure 4F was created with BioRender.com., The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed to revert high‐fat diet (HFD)‐induced obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno‐associated virus (AAV) to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key enzyme in FAO, in the liver of a mouse model of HFD‐induced obesity and NAFLD. Expression of hCPT1AM enhanced hepatic FAO and autophagy, reduced liver steatosis, and improved glucose homeostasis. Lipidomic analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9‐hCPT1AM administration and RYGB surgery, respectively, led to the identification of specific triacylglyceride (TAG) specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes, and NAFLD can reduce HFD‐induced derangements. Moreover, our study highlights TAG (C50:1) as a potential noninvasive biomarker that might be useful to monitor NAFLD in mice and humans., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Current challenges for targeting brown fat thermogenesis to combat obesity

  • Yoneshiro, Takeshi
  • Rodríguez-Rodríguez, Rosalía
  • Johannes Betz, Matthias
  • Rensen, Patrick C. N.
TY is supported by the research fellowship from the Uehara Memorial Foundation. RR-R is supported by the Spanish Ministry of Economy, Industry and Competitiveness (SAF2017-82813-C3-3R) and Joint Bilateral Project Japan-Spain/Agencia Estatal de Investigación (PCI2018-092997/AEI). MB is supported by the Swiss National Science Foundation (PZ00P3_167823). PCNR is supported by the Netherlands CardioVascular Research Initiative (CVON-GENIUS-II)., Just over a decade has passed since metabolically active brown adipose tissue (BAT) was unequivocally identified in healthy adult humans. Since then, researchers have provided evidence of expression of the thermogenic molecule uncoupling protein 1 (UCP1) in human BAT, as well as its energy dissipating capacity. Additionally, clinical cross-sectional analysis suggested that a decline in BAT activity with aging, as judged from [18F]FDG-PET/CT, coincides with the development of obesity and insulin resistance. These major observations provided a rationale to investigate BAT as a potential target for preventing obesity. Indeed, several studies have demonstrated that cold exposure and adrenomimetic agents strongly activate BAT thermogenesis, and thus energy expenditure in humans. However, the extent to which stimulating BAT thermogenesis decreases adiposity in humans remains unclear. Moreover, therapeutic strategies aimed at general stimulation of the sympathetic nervous system (SNS) and adrenergic receptors involved may not be applicable for obese and diabetic patients, because of potential negative side-effects on cardiovascular function., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Editorial: current challenges for targeting brown fat thermogenesis to combat obesity

  • Yoneshiro, Takeshi
  • Rodríguez-Rodríguez, Rosalía
  • Johannes Betz, Matthias
  • Rensen, Patrick C. N.
TY is supported by the research fellowship from the Uehara Memorial Foundation. RR-R is supported by the Spanish Ministry of Economy, Industry and Competitiveness (SAF2017-82813-C3-3R) and Joint Bilateral Project Japan-Spain/Agencia Estatal de Investigación (PCI2018-092997/AEI). MB is supported by the Swiss National Science Foundation (PZ00P3_167823). PCNR is supported by the Netherlands CardioVascular Research Initiative (CVON-GENIUS-II)., Just over a decade has passed since metabolically active brown adipose tissue (BAT) was unequivocally identified in healthy adult humans. Since then, researchers have provided evidence of expression of the thermogenic molecule uncoupling protein 1 (UCP1) in human BAT, as well as its energy dissipating capacity. Additionally, clinical cross-sectional analysis suggested that a decline in BAT activity with aging, as judged from [18F]FDG-PET/CT, coincides with the development of obesity and insulin resistance. These major observations provided a rationale to investigate BAT as a potential target for preventing obesity. Indeed, several studies have demonstrated that cold exposure and adrenomimetic agents strongly activate BAT thermogenesis, and thus energy expenditure in humans. However, the extent to which stimulating BAT thermogenesis decreases adiposity in humans remains unclear. Moreover, therapeutic strategies aimed at general stimulation of the sympathetic nervous system (SNS) and adrenergic receptors involved may not be applicable for obese and diabetic patients, because of potential negative side-effects on cardiovascular function. While implementation in humans remains challenging, recent studies in mice have yielded insights in molecular mechanisms underlying thermogenic regulation of brown and brown-like (brite/beige) adipocytes, highlighting their ability to reduce insulin resistance and atherosclerosis (1). These include identification of UCP1-independent thermogenesis as well as peripheral organ-derived endocrine factors and metabolites capable of triggering adipocyte thermogenesis. Activating these non-canonical mechanisms through genetic manipulation or pharmacological agents suppresses obesity and its associated complications in mice. The major challenge remains translating preclinical scientific advances to humans. To bridge basic research with clinical investigation, this Research Topic reviews the current advances in human BAT pathophysiology, novel molecular mechanisms regulating adipose thermogenesis, and remaining challenges in this field., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sensing of nutrients by CPT1C controls SAC1 activity to regulate AMPA receptor trafficking

  • Casas Prat, Maria
  • Fadó Andrés, Rut
  • Domínguez, José Luis
  • Roig, Aina
  • Kaku, Moena
  • Chohnan_, Shigeru
  • Solé, Montse
  • UNZETA, Mercedes
  • Miñano-Molina, Alfredo J
  • Rodriguez-Alvarez, Jose
  • Dickson, Eamonn
  • Casals, Nuria
This work was partially supported by Ministerio de Economia y Competitividad from Spain (grant SAF2017-82813-C3-3R to N. Casals, grant SAF2017-89271-R to J. Rodríguez-Alvarez, cofunded by the European Regional Development Fund), Centro de Investigación Biomedica en Red Fisiopatología de la Obesidad y la Nutrición (grant CB06/03/0001 to N. Casals), Centro de Investigación Biomedica en Red sobre Enfermedades Neurodegenerativas (grant CB06/05/0042 to J. Rodríguez-Alvarez), Generalitat de Catalunya (2014SGR465 to N. Casals, SGR2014-0984 to J. Rodríguez-Alvarez), Fundació La Marató de TV3 (grant 87/C/2016 to N. Casals, grant 2014-3610 to J. Rodríguez Alvarez), University of California funds (to E.J. Dickson)., Carnitine palmitoyltransferase 1C (CPT1C) is a sensor of malonyl-CoA and is located in the ER of neurons. AMPA receptors (AMPARs) mediate fast excitatory neurotransmission in the brain and play a key role in synaptic plasticity. In the present study, we demonstrate across different metabolic stress conditions that modulate malonyl-CoA levels in cortical neurons that CPT1C regulates the trafficking of the major AMPAR subunit, GluA1, through the phosphatidyl-inositol-4-phosphate (PI(4)P) phosphatase SAC1. In normal conditions, CPT1C down-regulates SAC1 catalytic activity, allowing efficient GluA1 trafficking to the plasma membrane. However, under low malonyl-CoA levels, such as during glucose depletion, CPT1C-dependent inhibition of SAC1 is released, facilitating SAC1’s translocation to ER-TGN contact sites to decrease TGN PI(4)P pools and trigger GluA1 retention at the TGN. Results reveal that GluA1 trafficking is regulated by CPT1C sensing of malonyl-CoA and provide the first report of a SAC1 inhibitor. Moreover, they shed light on how nutrients can affect synaptic function and cognition., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pomace olive oil concentrated in triterpenic acids restores vascular function, glucose tolerance and obesity progression in mice

  • Claro-Cala, Carmen Maria
  • Quintela, Jose Carlos
  • Pérez-Montero, Marta
  • Miñano, Javier
  • Alvarez de Sotomayor, María
  • Dolores Herrera, María
  • Rodríguez-Rodríguez, Rosalía
This work was supported by the Spanish Ministerio de Economía, Industria y Competitividad (MINECO), Agencia Estatal de Investigación (AEI), and Fondo Europeo de Desarrollo Regional (FEDER) (Grants SAF2017-82813-C3-3-R and PCI2018-092997/AEI to R.R.-R.)., Pomace olive oil, an olive oil sub-product, is a promising source of bioactive triterpenoids such as oleanolic acid and maslinic acid. Considering the vascular actions of pomace olive oil and the potential effects of the isolated oleanolic acid on metabolic complications of obesity, this study investigates for the first time the dietary intervention with a pomace olive oil with high concentrations of the triterpenic acids (POCTA), oleanolic and maslinic acid, during diet-induced obesity in mice. The results demonstrate that obese mice, when switched to a POCTA-diet for 10 weeks, show a substantial reduction of body weight, insulin resistance, adipose tissue inflammation, and particularly, improvement of vascular function despite high caloric intake. This study reveals the potential of a functional food based on pomace olive oil and its triterpenic fraction against obesity progression. Our data also contribute to understanding the health-promoting effects attributable to the Mediterranean diet., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sensing of nutrients by CPT1C controls SAC1 activity to regulate AMPA receptor trafficking

  • Casas, Maria
  • Rut, Fadó
  • Domínguez, José Luis
  • Roig, Aina
  • Kaku, Moena
  • Chohnan, Shigeru
  • Solé, Montse
  • Unzeta, Mercedes
  • Miñano Molina, Alfredo Jesús
  • Rodríguez-Álvarez, José
  • James Dickson, Eamonn
  • Casals i Farré, Núria
This work was partially supported by Ministerio de Economia y Competitividad from Spain (grant SAF2017-82813-C3-3R to N. Casals, grant SAF2017-89271-R to J. Rodr´ıguez-Alvarez, cofunded by the European Regional Development Fund), Centro de Investigación Biomedica en Red Fisiopatologıa de la Obesidad y la Nutrición (grant CB06/03/0001 to N. Casals), Centro de Investigación Biomedica en Red sobre Enfermedades Neuro- degenerativas (grant CB06/05/0042 to J. Rodrıguez-Alvarez), Generalitat de Catalunya (2014SGR465 to N. Casals, SGR2014-0984 to J. Rodr´ıguez-Alvarez), Fundació La Marató de TV3 (grant 87/C/2016 to N. Casals, grant 2014-3610 to J. Rodr´ıguezAlvarez), University of California funds (to E.J. Dickson), and National Institutes of Health grant R01 GM127513 (to E.J. Dickson)., Carnitine palmitoyltransferase 1C (CPT1C) is a sensor of malonyl-CoA and is located in the ER of neurons. AMPA receptors (AMPARs) mediate fast excitatory neurotransmission in the brain and play a key role in synaptic plasticity. In the present study, we demonstrate across different metabolic stress conditions that modulate malonyl-CoA levels in cortical neurons that CPT1C regulates the trafficking of the major AMPAR subunit, GluA1, through the phosphatidyl-inositol-4-phosphate (PI(4)P) phosphatase SAC1. In normal conditions, CPT1C down-regulates SAC1 catalytic activity, allowing efficient GluA1 trafficking to the plasma membrane. However, under low malonyl-CoA levels, such as during glucose depletion, CPT1C-dependent inhibition of SAC1 is released, facilitating SAC1’s translocation to ER-TGN contact sites to decrease TGN PI(4)P pools and trigger GluA1 retention at the TGN. Results reveal that GluA1 trafficking is regulated by CPT1C sensing of malonyl-CoA and provide the first report of a SAC1 inhibitor. Moreover, they shed light on how nutrients can affect synaptic function and cognition., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sensing of nutrients by CPT1C controls SAC1 activity to regulate AMPA receptor trafficking

  • Casas, Maria
  • Fadó Andrés, Rut
  • Domínguez, José Luis
  • Roig, Aina
  • Kaku, Moena
  • Chohnan, Shigeru
  • Solé, Montse
  • Unzeta, Mercedes
  • Miñano Molina, Alfredo Jesús
  • Rodríguez-Álvarez, José
  • Dickson, Eamonn James
  • Casals i Farré, Núria
This work was partially supported by Ministerio de Economia y Competitividad from Spain (grant SAF2017-82813-C3-3R to N. Casals, grant SAF2017-89271-R to J. Rodrıguez-Alvarez, cofunded ´by the European Regional Development Fund), Centro de Investigación Biomedica en Red Fisiopatologıa de la Obesidad y la Nutrición (grant CB06/03/0001 to N. Casals), Centro de Investigación Biomedica en Red sobre Enfermedades Neuro- ´degenerativas (grant CB06/05/0042 to J. Rodrıguez-Alvarez), ´Generalitat de Catalunya (2014SGR465 to N. Casals, SGR2014-0984 to J. Rodr´ıguez-Alvarez), Fundació La Marató de TV3 ´(grant 87/C/2016 to N. Casals, grant 2014-3610 to J. RodrıguezAlvarez), University of California funds (to E.J. Dickson), and ´National Institutes of Health grant R01 GM127513 (to E.J. Dickson)., Carnitine palmitoyltransferase 1C (CPT1C) is a sensor of malonyl-CoA and is located in the ER of neurons. AMPA receptors (AMPARs) mediate fast excitatory neurotransmission in the brain and play a key role in synaptic plasticity. In the present study, we demonstrate across different metabolic stress conditions that modulate malonyl-CoA levels in cortical neurons that CPT1C regulates the trafficking of the major AMPAR subunit, GluA1, through the phosphatidyl-inositol-4-phosphate (PI(4)P) phosphatase SAC1. In normal conditions, CPT1C down-regulates SAC1 catalytic activity, allowing efficient GluA1 trafficking to the plasma membrane. However, under low malonyl-CoA levels, such as during glucose depletion, CPT1C-dependent inhibition of SAC1 is released, facilitating SAC1’s translocation to ER-TGN contact sites to decrease TGN PI(4)P pools and trigger GluA1 retention at the TGN. Results reveal that GluA1 trafficking is regulated by CPT1C sensing of malonyl-CoA and provide the first report of a SAC1 inhibitor. Moreover, they shed light on how nutrients can affect synaptic function and cognition., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sensing of nutrients by CPT1C regulates late endosome/lysosome anterograde transport and axon growth

  • Palomo Guerrero, Marta
  • Fadó Andrés, Rut
  • Casas, Maria
  • Pérez-Montero, Marta
  • Baena, Miguel
  • Helmer, Patrick O.
  • Domínguez, José Luis
  • Roig, Aina
  • Serra, Dolors
  • Hayen, Heiko
  • Stenmark, Harald
  • Raiborg, Camilla
  • Casals i Farré, Núria
We are very grateful to Eva M Wenzel for her help in the settings of live imaging experiments and critical discussion. This work was supported by the Ministry of Spain (MINECO) (Grants SAF2014- 52223-C2-1-R to DS, SAF2017-83813-C3-1-R to DS, SAF2014-52223-C2-2-R to NC, and SAF2017- 82813-C3-3R to NC, cofunded by the European Regional Development Fund [ERDF]), the Centro de Investigacion Biomedica en Red Fisiopatologı´a de la Obesidad y la Nutricion (CIBEROBN) (Grant CB06/03/0001 to DS), the Generalitat de Catalunya (2014SGR465 to DS and NC), Fundacio´ La Marato´ de TV3 (Grant 87/C/2016 to DS and NC). POH thanks the Fonds der Chemischen Industrie (FCI, Frankfurt am Main, Germany) for a PhD scholarship. The authors declare no competing financial interests., Anterograde transport of late endosomes or lysosomes (LE/Lys) is crucial for proper axon growth. However, the role of energetic nutrients has been poorly explored. Malonyl-CoA is a precursor of fatty acids, and its intracellular levels highly fluctuate depending on glucose availability or the energy sensor AMP-activated protein kinase (AMPK). We demonstrate in HeLa cells that carnitine palmitoyltransferase 1C (CPT1C) senses malonyl-CoA and enhances LE/Lys anterograde transport by interacting with the endoplasmic reticulum protein protrudin and facilitating the transfer of Kinesin-1 from protrudin to LE/Lys. In cultured mouse cortical neurons, glucose deprivation, pharmacological activation of AMPK or inhibition of malonyl-CoA synthesis decreases LE/Lys abundance at the axon terminal, and shortens axon length in a CPT1C-dependent manner. These results identify CPT1C as a new regulator of anterograde LE/Lys transport in response to malonyl-CoA changes, and give insight into how axon growth is controlled by nutrients., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sensing of nutrients by CPT1C controls SAC1 activity to regulate AMPA receptor trafficking

  • Casas, Maria|||0000-0002-5246-8874
  • Fadó, Rut|||0000-0002-3293-2342
  • Domínguez, José Luis
  • Roig, Aina
  • Kaku, Moena
  • Chohnan, Shigeru|||0000-0002-4624-927X
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Miñano Molina, Alfredo Jesús|||0000-0002-7761-5682
  • Rodríguez Álvarez, José|||0000-0001-8582-8082
  • Dickson, Eamonn James|||0000-0001-8619-7630
  • Casals, Nuria|||0000-0002-6719-4300
GuA1-containing AMPA receptors play a key role in synaptic plasticity and cognition. Casas et al. demonstrate that the sensing of nutrients by CPT1C regulates the phosphatase activity of SAC1, and consequently PI(4)P levels, at the contact sites between the endoplasmic reticulum and the trans-Golgi network to control the trafficking of GluA1 receptors to the cell surface of neurons. Carnitine palmitoyltransferase 1C (CPT1C) is a sensor of malonyl-CoA and is located in the ER of neurons. AMPA receptors (AMPARs) mediate fast excitatory neurotransmission in the brain and play a key role in synaptic plasticity. In the present study, we demonstrate across different metabolic stress conditions that modulate malonyl-CoA levels in cortical neurons that CPT1C regulates the trafficking of the major AMPAR subunit, GluA1, through the phosphatidyl-inositol-4-phosphate (PI(4)P) phosphatase SAC1. In normal conditions, CPT1C down-regulates SAC1 catalytic activity, allowing efficient GluA1 trafficking to the plasma membrane. However, under low malonyl-CoA levels, such as during glucose depletion, CPT1C-dependent inhibition of SAC1 is released, facilitating SAC1's translocation to ER-TGN contact sites to decrease TGN PI(4)P pools and trigger GluA1 retention at the TGN. Results reveal that GluA1 trafficking is regulated by CPT1C sensing of malonyl-CoA and provide the first report of a SAC1 inhibitor. Moreover, they shed light on how nutrients can affect synaptic function and cognition.